pdf

Media Outlets Note O’Melveny’s Role in Angiotech Deal

December 19, 2016

A number of media outlets, including The Deal and India Investment News, recently reported that O’Melveny represented Vivo Capital in its acquisition, along with other investors, of Canadian medical device maker Angiotech Pharmaceuticals.

In its December 19, 2016 article “Investor Group Acquires Struggling Angiotech,” The Deal reported that the consortium of investors will add Angiotech “to its portfolio of biotechs and drug researchers across North America.”

To learn more, view our press release.